Pharma BD Deal Intelligence

Cephalon, Inc. / Mesoblast Limited

2010 · Licensing/Option · $2.0B · Complete

Cephalon and Mesoblast strategic alliance: $130M upfront + up to $1.7B regulatory milestones for exclusive worldwide rights to MPC therapeutics in CV/CNS. Cephalon also took 19.99% equity stake. Largest licensing deal of 2010.

Key facts

• Announced Dec 07, 2010
• Deal value $2.0B
• Deal type Licensing/Option
• Therapeutic area CHF; acute MI; Parkinson's; Alzheimer's; HSC transplant augmentation
• Indications CHF; acute MI; Parkinson's; Alzheimer's; HSC transplant augmentation
• Key assets Mesenchymal Precursor Cell (MPC) therapies
• Mechanism Allogeneic mesenchymal precursor cell therapy

← Browse all deals  ·  How we score deals